Hormone Profiles with Valproate Monotherapy

Visual function in epilepsy patients treated with initial valproate monotherapy

PURPOSE To investigate whether initial valproate (VPA) monotherapy for the treatment of epilepsy causes visual field defects and visual dysfunction. METHODS In a cross-sectional study, visual fields were examined with the kinetic Goldmann and automated Humphrey perimeters, contrast sensitivity function with the Pelli-Robson letter chart and colour vision with the Standard Pseudoisochromatic P...

Hepatic functions in epileptics on sodium valproate monotherapy.

Sodium valproate (VPA) has been advocated as an antiepileptic of first choice in patients of primary generalised seizures (1) because of low risks of serious side effects and negligible neuropsychiatric manifestations. However, it has been clinically and experimentally observed to induce hepatic dysfunction including hepatic failure resulting in fatalities making periodic screening for liver fu...

Changes in cognitive functions in epileptics on sodium valproate monotherapy.

Virtually all anti-epileptic drugs (A.E.n's) can affect mental functions. Greater attention is now being given by epileptologists in assessing cognitive effects of A.E.D's with a view to offer the patients excellent seizure control with least possible negative impact in cognition. Sodium valproate has the advantage of causing minimal dysfunction in cognitive functions as compared to other well ...

Serum Lipids and Thyroid Functions in Young Epileptic Patients Undergoing Monotherapy with Valproate or Levetiracetam

The negative side effects of classic antiepileptics, such as Valproate (VPA), often cause patients to discontinue their use. While the negative effects of VPA on lipid profile and thyroid functions have been well published, data regarding the side effects of new antiepileptics, such as levetiracetam (LEV), are not as conclusive. In this study, we investigated the effects of a well-known antiepi...

Trace Elements, Antioxidant Enzymes and Free Carnitine Levels Among Epileptic Patients Treated with Valproate Monotherapy